Jerzy Pręgowski, Radosław Pracoń, Aleksandra Mioduszewska, Jarosław Skowroński, Lars Sondergaard, Gary S Mintz, Davide Capodanno, Sang-Wook Kim, Ole De Baker, Piotr Waciński, Wojciech Wojakowski, Adam Rdzanek, Marek Grygier, Michał Chmielecki, Luis Nombela Franco, Patrycjusz Stokłosa, Bohdan Firek, Magdalena Marczak, Barbara Miłosz, Zbigniew Chmielak, Marcin Demkow, Adam Witkowski
BACKGROUND: Both transcatheter edge-to-edge repair (TEER) of mitral regurgitation or left atrial appendage closure (LAAC) require periprocedural anticoagulation with unfractionated heparin (UFH) that is administered either before or immediately after transseptal puncture (TSP). The optimal timing of UFH administration (before or after TSP) is unknown. The Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions trial (STOP CLOT Trial) was designed to determine if early anticoagulation is effective in reducing ischemic complications without increasing the risk of periprocedural bleeding...
February 22, 2024: American Heart Journal